公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2014 | All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: A multinational, phase 3, multicohort study | Manns M.; Pol S.; Jacobson I.M.; Marcellin P.; Gordon S.C.; Peng C.-Y.; Chang T.-T.; Everson G.T.; Heo J.; Gerken G.; Yoffe B.; Towner W.J.; Bourliere M.; Metivier S.; Chu C.-J.; Sievert W.; Bronowicki J.-P.; Thabut D.; Lee Y.-J.; JIA-HORNG KAO ; McPhee F.; Kopit J.; Mendez P.; Linaberry M.; Hughes E.; Noviello S. | The Lancet | 299 | 276 | |
2011 | Alpha-fetoprotein in chronic hepatitis C | Hsu C.-S.; JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
1997 | Amplification of GB virus-C/hepatitis G virus RNA with primers from different regions of the viral genome | JIA-HORNG KAO ; PEI-JER CHEN ; Chen W.; Hsiang S.C.; Lai M.Y.; DING-SHINN CHEN | Journal of Medical Virology | 50 | | |
2023 | Anti-HBc level predicting virological relapse after stopping nucleos(t)ide analogue in chronic hepatitis B | Huang, Chiuan-Bo; TUNG-HUNG SU ; JIA-HORNG KAO | Liver international : official journal of the International Association for the Study of the Liver | 1 | 1 | |
1999 | Antiandrogen hepatotoxicity in patients with chronic viral hepatitis | YEONG-SHIAU PU ; Liu C.-M.; JIA-HORNG KAO ; Chen J.; Lai M.-K. | European Urology | 24 | 13 | |
2020 | Antiviral therapy against chronic hepatitis C is associated with a reduced risk of oral cancer | TUNG-HUNG SU ; TAI-CHUNG TSENG ; CHUN-JEN LIU ; Chou S.-W; CHEN-HUA LIU ; HUNG-CHIH YANG ; PEI-JER CHEN ; DING-SHINN CHEN ; CHI-LING CHEN ; JIA-HORNG KAO | International Journal of Cancer | 4 | 4 | |
2019 | Antiviral Therapy in Patients With Chronic Hepatitis C Is Associated With a Reduced Risk of Parkinsonism | TUNG-HUNG SU ; HUNG-CHIH YANG ; TAI-CHUNG TSENG ; Chou S.-W; CHIN-HSIEN LIN ; CHEN-HUA LIU ; CHUN-JEN LIU ; CHI-LING CHEN ; JIA-HORNG KAO | Movement Disorders | 14 | 14 | |
2022 | APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis | You H.; Ma X.; Efe C.; Wang G.; Jeong S.-H.; Abe K.; Duan W.; Chen S.; Kong Y.; Zhang D.; Wei L.; Wang F.-S.; Lin H.-C.; Yang J.M.; Tanwandee T.; Gani R.A.; Payawal D.A.; Sharma B.C.; Hou J.; Yokosuka O.; Dokmeci A.K.; Crawford D.; JIA-HORNG KAO ; Piratvisuth T.; Suh D.J.; Lesmana L.A.; Sollano J.; Lau G.; Sarin S.K.; Omata M.; Tanaka A.; Jia J. | Hepatology International | 35 | 19 | |
2019 | APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment? | Kanda T.; Lau G.K.K.; Wei L.; Moriyama M.; Yu M.-L.; Chuang W.-L.; Ibrahim A.; Lesmana C.R.A.; Sollano J.; Kumar M.; Jindal A.; Sharma B.C.; Hamid S.S.; Dokmeci A.K.; Mamun-Al-Mahtab, McCaughan G.W.; Wasim J.; Crawford D.H.G.; JIA-HORNG KAO ; Yokosuka O.; Sarin S.K.; Omata M. | Hepatology International | 31 | 27 | |
2012 | APASL consensus statements and management algorithms for hepatitis C virus infection | Omata M.; Kanda T.; Yu M.-L.; Yokosuka O.; Lim S.-G.; Jafri W.; Tateishi R.; Hamid S.S.; Chuang W.-L.; Chutaputti A.; Wei L.; Sollano J.; Sarin S.K.; JIA-HORNG KAO ; McCaughan G.W. | Hepatology International | 143 | 132 | |
2016 | APASL consensus statements and recommendation on treatment of hepatitis C | Omata M.; Kanda T.; Wei L.; Yu M.-L.; Chuang W.-L.; Ibrahim A.; Lesmana C.R.A.; Sollano J.; Kumar M.; Jindal A.; Sharma B.C.; Hamid S.S.; Dokmeci A.K.; Mamun-Al-Mahtab, McCaughan G.W.; Wasim J.; Crawford D.H.G.; JIA-HORNG KAO ; Yokosuka O.; Lau G.K.K.; Sarin S.K. | Hepatology International | 185 | 167 | |
2016 | APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing | Omata M.; Kanda T.; Wei L.; Yu M.-L.; Chuang W.-L.; Ibrahim A.; Lesmana C.R.A.; Sollano J.; Kumar M.; Jindal A.; Sharma B.C.; Hamid S.S.; Dokmeci A.K.; Al-Mahtab M.; McCaughan G.W.; Wasim J.; Crawford D.H.G.; JIA-HORNG KAO ; Yokosuka O.; Lau G.K.K.; Sarin S.K. | Hepatology International | 72 | 70 | |
2021 | APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients | JIA-HORNG KAO ; Jeng W.-J.; Ning Q.; TUNG-HUNG SU ; TAI-CHUNG TSENG ; Ueno Y.; Yuen M.-F. | Hepatology International | 39 | 28 | |
2019 | APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation | Kanda T.; Lau G.K.K.; Wei L.; Moriyama M.; Yu M.-L.; Chuang W.-L.; Ibrahim A.; Lesmana C.R.A.; Sollano J.; Kumar M.; Jindal A.; Sharma B.C.; Hamid S.S.; Kadir Dokmeci A.; Mamun-Al-Mahtab, McCaughan G.W.; Wasim J.; Crawford D.H.G.; JIA-HORNG KAO ; Ooka Y.; Yokosuka O.; Sarin S.K.; Omata M. | Hepatology International | 67 | 63 | |
2005 | Application of hepatitis B virus genotyping and phylogenetic analysis in intrafamilial transmission of hepatitis B virus | Lin C.-L.; JIA-HORNG KAO ; Chen B.-F.; PEI-JER CHEN ; Lai M.-Y.; DING-SHINN CHEN | Clinical Infectious Diseases | 41 | 36 | |
2007 | Appropriate use of interferon for treatment of chronic hepatitis B | JIA-HORNG KAO | Hepatology Research | 20 | 17 | |
2007 | APRI-M6 for predicting long-term outcome of chronic hepatitis C patients after interferon-based therapy: More questions than answers [5] | TUNG-HUNG SU ; JIA-HORNG KAO ; DING-SHINN CHEN | Hepatology | 0 | 0 | |
2015 | Artificial ascites is feasible and effective for difficult-to-ablate hepatocellular carcinoma | Wang C.-C.; JIA-HORNG KAO | Hepatology International | 27 | 27 | |
2023 | Artificial intelligence in precision medicine and liver disease monitoring | TUNG-HUNG SU ; JIA-HORNG KAO | Artificial Intelligence, Machine Learning, and Deep Learning in Precision Medicine in Liver Diseases: Concept, Technology, Application and Perspectives | | | |
2021 | Artificial intelligence in precision medicine in hepatology | TUNG-HUNG SU ; CHIH-HORNG WU ; JIA-HORNG KAO | Journal of gastroenterology and hepatology | 30 | 23 | |